J&J reports positive data from late-stage Tremfya study

Johnson & Johnson (JNJ) reported positive data from a late stage study of Tremfya for the treatment of active psoriatic ...
abc27

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...
Monthly Prescribing Reference

Tremfya Approved for Children With Plaque Psoriasis, Psoriatic Arthritis

The recommended dosage for active PsA and moderate to severe plaque PsO in pediatric patients 6 years (≥40kg) is 100mg administered SC at week 0, 4, and then every 8 weeks thereafter. The Food and ...

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit ...
Morningstar

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
KRQE Blogs

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

"Historically, IL-23 inhibitors have required IV infusions at the start of therapy, which can create barriers to starting treatment or be burdensome for some patients and clinicians," said David T.
Hosted on MSN

FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults with ...
Nasdaq

JNJ Studies Show Positive Impact Of TREMFYA In Crohn's Disease Patients

(RTTNews) - Johnson & Johnson (JNJ), Monday announced findings from the long-term extensions of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, showing impact of TREMFYA in adults with moderately ...